Tag: Corcept Therapeutics
December 13, 2018
Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
Corcept Therapeutics (NASDAQ:CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow... November 19, 2018
Corcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant
Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and... August 10, 2018
Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides Clinical Update
Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and... May 9, 2018
Corcept Therapeutics Announces First Quarter 2018 Financial results and Provides Corporate Update
Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and... March 16, 2018
Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals for Infringement of Korlym Patents
Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and... February 23, 2018
Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial
Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and... May 4, 2017